Trial Profile
An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs RG 4929 (Primary)
- Indications Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Roche
- 26 Jun 2014 New trial record